Teva and Medincell announced on Wednesday positive results from their Phase 3 clinical trial of their long-acting experimental treatment for schizophrenia.

The study, which was designed to measure the efficacy of a monthly subcutaneous long-acting injection of olanzapine, met its primary endpoint in all groups receiving TV-'749 doses compared with the placebo group.

The Israeli generic company and its French partner even reported 'clinically remarkable' and statistically significant reductions in the total score on the Positive and Negative Symptoms Scale (PANSS), a widely used assessment tool for gauging the severity of schizophrenia symptoms.

At present, there is no option for treating schizophrenia with long-acting olanzapine without the risk of post-injection delirium/sedation syndrome (PDSS).

As such, the development of new innovative long-acting therapeutic options could better address the needs of these patients, who often experience relapse episodes.

Teva and Medincell specify that further efficacy and safety results from the phase 3 study are expected to be presented at a scientific conference later this year.

An estimated 3.5 million people are currently diagnosed with schizophrenia in the US alone.

Medincell announced this morning that it had requested the suspension of trading in its shares on the Paris Bourse pending the publication of a press release.

Trading in its shares is due to resume tomorrow at the opening of the markets.

Copyright (c) 2024 CercleFinance.com. All rights reserved.